No Data
No Data
RBC Capital Maintains Sophia Genetics(SOPH.US) With Buy Rating, Maintains Target Price $7
RBC Capital Keeps Their Buy Rating on SOPHiA GENETICS (SOPH)
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024
GENETICS Presents AI-Driven Patient Stratification Research For NSCLC Immunotherapy At ESMO 2024
SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024
SOPHiA GENETICS And AstraZeneca Collaborate To Further Expand Global Access To Liquid Biopsy Testing; SOPHiA GENETICS Will Accelerate The Deployment Of MSK-ACCESS Powered With SOPHiA DDM To 20 Locations Worldwide Over The Next 12 Months